COPID19. Worldwide survey of COVID-19 in PID patients
With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals.
The COVID Human Genetic Effort
Dear Friends and Colleagues,
Please find here a study proposal on behalf of Jean-Laurent Casanova, Lab of Human Genetics of Infectious Diseases, The Rockefeller University & HHMI, New York - Necker Hospital for Sick Children & INSERM, Paris.
ESID COVID-19 Statement
Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease clinical phenotypes and biology, improving treatment and implementing vaccination trials. While there remains relatively little published information about the impacts of COVID-19 for patients with Primary Immunodeficiency (PID), data are gradually emerging. The purpose of this statement is to summarise what we know so far and set out ESID’s current guidance for professionals in the PID community in Europe. We will update this statement as evidence emerges.
« Previous 1 2